associated with reduced survival without neonatal morbidity (0.65 (0.54-0.77), p < 0.0001) and survival without neurodevelopmental impairment at 2 years (0.70(0.57-0.85), p < 0.001). After correction for gestational age and birth weight z-score, no significant association between any measure of neonatal glycaemia and neonatal or 2 year outcomes remained.
University of Auckland, Liggins Institute
Background: The long-term effects of tight glycaemic control of neonatal hyperglycaemia are not known.
Method: Children randomised as neonates to a trial of tight vs. standard glycaemic control were assessed at 7 years' corrected age, including Wechsler Intelligence Scale for Children (4 th Ed), Movement Assessment Battery for Children-2, visual acuity, neurological examination, dual x-ray absorptiometry and growth measures. The primary outcome was survival without neurodevelopmental impairment at age 7. Outcomes were compared using linear regression, adjusted for sex, small for gestational age, birth plurality, and the clustering of twins. Body composition measures were also adjusted for height. Data are number (%) or mean AE SD.
Results: Of 88 infants randomised, 20 (23%) were not assessed at 7 years; thus, the primary outcome was available in 68 (77%) children, including 11 (13%) who had died. Survival without neurodevelopmental impairment occurred in 25 / 68 (37%), with no difference between tight (14/35 (40%)) and standard (11/33 (33%)) glycaemic control groups (p = 0.6). Children in the tight group were shorter than those in the standard group (121.3 AE 6.3 vs. 125.1 AE 5.4 cm, p < 0.05), but similar in weight and head circumference. Children in the tight group had more height-adjusted lean mass (18.7 AE 0.3 vs. 17.6 AE 0.2 kg, p < 0.01), but similar fat mass and bone mineral density.
Conclusions: Tight glycaemic control for neonatal hyperglycaemia does not change survival without neurodevelopmental impairment, but does result in reduced height and greater height-adjusted lean mass at school age. Background: Management of infants at risk of Neonatal Abstinence Syndrome (NAS) varies between centres, particularly in relation to in-hospital management. Our practice includes using higher treatment thresholds, observation on postnatal wards, minimisation of NICU admission and early discharge with regular outpatient follow-up.
MANAGEMENT OF INFANTS WITH NEONATAL
Methods: We retrospectively reviewed the records of all inborn infants with a history of maternal perinatal opiate exposure presenting to our perinatal service between the years of 2009 and 2014.
Results: 147 infants at risk of NAS were identified. All infants were seen on outpatient follow-up for a median duration of 9 months (iqr 6-12). 55% (n = 81) were diagnosed with NAS using the modified Finnegan's Scale at a median postnatal age of 2 days. The table below displays the salient features of these infants. All infants requiring treatment with morphine were discharged on oral medication. Morphine was weaned on an outpatient basis with median length of treatment being 42 days (iqr 33-54). Importantly, none of the infants in the study required adjunct pharmacological treatment or readmission for NAS related health concerns.
Infants with NAS = 81

NICU admission for NAS [Percentage (number)]
21% (17 Murdoch Childrens Research Institute Background: Children born very preterm (VPT; <32 weeks' gestation) have increased risk for developmental impairments, and their mothers have higher rates of depression and anxiety symptoms across the early years. The aim of the study was to examine whether maternal depression and anxiety symptoms over the first 2 years of life was associated with development in VPT children.
Method: Participants were 149 children born <30 weeks' gestation and their mothers. Maternal depression and anxiety symptoms were assessed at birth, 12, and 24 months', and children's cognitive, language, and social-emotional development was assessed at 24 months corrected age.
Results: Maternal depression or anxiety at birth, 12 or 24 months' corrected age was not associated with cognitive or language development at 24 months. Increased symptoms of depression or anxiety at 12 or 24 months were strongly associated with increased externalising, internalising, dysregulation behaviours and decreased social competence at 24 months (all p <.05). Longer duration of elevated depression or anxiety symptoms (at least 2/3 times) was associated with children scoring on average almost one full standard deviation (0.9 SD, or 9 points) higher on externalising, internalising and dysregulation scales, reflecting greater difficulties.
Conclusions: Mental health of mothers who have a VPT infant is strongly associated with social, emotional and behavioural functioning in their child. This has implications for screening for high-risk infants and highlights the need for longterm follow up and support for parents after VPT birth. School of Psychology Background: We present a pilot randomised trial to test study feasibility and plausibility of the hypothesis that STan intrapartum fetal monitoring (cardiotocographic plus electrocardiographic ST analysis) as compared with cardiotocographic (CTG) monitoring alone, will reduce emergency caesarean section. We also conducted qualitative research with pregnant women, and midwives and obstetricians to identify associated psychosocial and organisational issues.
Method: 162 women were randomised. Semi-structured interviews incorporating hypothetical written scenarios were conducted with 11 pregnant women, and 10 midwives and 8 doctors.
Results: Emergency caesarean section was performed on 11/82 (13.4%) women randomised to STan and 17/80 women randomised to CTG (21.2%). Women's views about monitoring were multifaceted and influenced by the following factors: risk and mobility in labour, autonomy and choice in labour and trust in maternity providers. Midwives and doctors indicated four important areas for consideration when introducing STan: philosophy of care, training and education, research evidence and attitudes to new technology.
Conclusions: Being a pilot, the clinical result is not expected to be statistically significant but does support hypothesis plausibility. The study is currently being initiated as an appropriately powered randomised trial. Method: We model perinatal inflammation-induced white matter injury in mice by injecting interleukin-1B (IL-1B, 10ng/ kg) twice daily from postnatal (P)1-P5 (3rd trimester equivalent in humans). This mimics keystone facets of brain injury in preterm infants (Favrais et al., 2012. Ann Neurol) . Specific neuroinflammation analyses: validation of the requirement for MG in injury (gadolinium knockout of pro-inflammatory MG), acute & long-term profile of inflammatory cells with FACS, MG phenotype using MACS-extraction of CD11b positive cells followed by microarray, supplemented with qRT-PCR for phenotype markers. Functional pathways from transcriptomics analysis were validated in human MG in vitro and nanoparticles able to specifically target MG in vivo were used to deliver immunomodulatory therapies.
MICROGLIAL ACTIVATION IN PERINATAL INFLAMMATION-INDUCED WHITE MATTER INJURY
Results: MG are required for injury in this model, and we validated bioinformatics analysis in vitro and in vivo to reveal a novel role for the Wnt pathway in regulating MG activation to an oligodendrocyte damaging phenotype. We verified this link in human MG, and using an integrated analysis of white matter tractography and genetic polymorphisims we found an association between MRI findings and Wnt in human preterm patients.
Conclusions: Wnt pathway mediated microglial activation is a novel pathway that is sufficient and necessary for inflammation mediated white matter injury in this model of preterm brain injury. 
LONG-TERM TRENDS IN SPONTANEOUS AND
